By Stephen Nakrosis
Shares of Wave Life Sciences were trading lower after hours following news the company commenced a $100 million underwritten public offering.
The company will offer ordinary shares and, to certain investors, pre-funded warrants to buy ordinary shares, it said Wednesday.
After the bell, the company’s shares were trading 19.8% lower at $5.51 each. The stock closed the day’s regular session with a 9.2% gain, finishing at $6.87.
Also on Wednesday, Wave Life said it commenced dosing in healthy volunteers in its RestorAATion clinical trial program to study WVE-006 as a potential treatment for alpha-1 antitrypsin deficiency, which can increase the risk of lung and other diseases.
Write to Stephen Nakrosis at [email protected]
Read the full article here